Frontlight ResearchEarly access
Taking people in ItalyPhase 2
Tests stereotactic radiation with or without a second agent in prostate cancer
Tests stereotactic radiation with or without sTad in men with prostate cancer.
Key facts
- Who runs it
- I.F.O. Istituti Fisioterapici Ospitalieri
- Where
- Milan, Rome, and Trieste, ItalySee the 3 sites
- Registry title
- Sbrt±sTad for Unfavorable iNtermediate rIsk/high-risk prostate cancer (STUNNIN): A Randomized Phase II Study
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 146 people, planned
- Started
- 29 Apr 2024
- Planned end
- 8 Mar 2026
- Type of study
- Interventional
- Record updated
- 13 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer of unfavorable intermediate or high risk that has not spread to lymph nodes or other organs. It compares radiotherapy with and without short-term hormone therapy.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Prostate adenocarcinoma, intermediate or high risk by the NCCN definition, with no spread to lymph nodes or distant organs (N0M0) on a PET-CT scan. ECOG performance status 0 to 2.
- Earlier treatment
- Cannot join if they had surgery or cryotherapy on the prostate, radiotherapy to the pelvis, or chemotherapy for cancer in the past 5 years.
Main reasons for not taking part
- T3b disease (8th AJCC classification)
- PSA above 20 ng/ml at any time
- Gleason Score of 9 or 10
- Cannot have fiducials implanted or cannot have a prostate MRI
- Prostate volume above 90cc
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Histologically proven prostate adenocarcinoma - IR or HR in the NCCN definition - N0M0 at staging with choline or (preferably) PSMA PET-CT; - ECOG performance status between 0 and 2
Who cannot take part
- T3b disease according to the 8th AJCC classification; - PSA>20 ng/ml at any time point - Gleason Score of 9 or 10 (Grade Grouping V) - Previous local treatment of the prostate with surgery (radical prostatectomy or cryotherapy) - Previous radiotherapy to the pelvis - Previous chemotherapy for malignancy in past 5 years - Impossibility to implant fiducials for tracking purposes - Impossibility to undergo MRI of the prostate - Contraindication to short term AD - Prostate volume >90cc
Where in Italy
- San Raffaele HospitalMilan, ItalyTaking people
- I.F.O. Istituti Fisioterapici OspitalieriRome, ItalyTaking people
- Azienda Sanitaria Universitaria Giuliano IsontinaTrieste, ItalyTaking people
About the trial
What the trial wants to find out
the primary objective of the study is 3-year bNED survival. If bNED survival is not significantly different between the two experimental arms, the one without AD will be chosen in a future comparison with the standard of care.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Sbrt±sTad for Unfavorable iNtermediate rIsk/high-risk prostate cancer (STUNNIN): A Randomized Phase II Study
- Plain-language title
- Tests stereotactic radiation with or without a second agent in prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 13 July 2026